$224.91 0.0 0.0%
Last Trade - 16/11/20
| Market Cap | ÂŁ8.83bn |
| Enterprise Value | ÂŁ8.17bn |
| Revenue | ÂŁn/a |
| Position in Universe | th / 6547 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020E | 2021E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 5.92 | 14.2 | 42.0 | 11.4 | 33.6 | 0.000 | 18.4 | -100.0% | |||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
MyoKardia, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics. The Company has used its precision medicine platform to generate an initial pipeline of over four therapeutic programs for the chronic treatment of two forms of heritable cardiomyopathy-hypertrophic cardiomyopathy (HCM), and dilated cardiomyopathy (DCM). Additionally, the Company has three preclinical programs, HCM-2, DCM-2 and LUS-1. Its lead product candidate, MYK-461, is an orally-administered small molecule designed to reduce excessive cardiac muscle contractility leading to HCM.
| Last Annual | December 31st, 2019 |
| Last Interim | September 30th, 2020 |
| Incorporated | June 8, 2012 |
| Public Since | October 29, 2015 |
| No. of Shareholders: | 6 |
| No. of Employees: | 318 |
| Sector | Healthcare |
| Industry | Biotechnology & Medical Research |
| Index | |
| Exchange | NASDAQ Global Select Market |
| Shares in Issue | 53,322,904 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | 1000 Sierra Point Parkway, BRISBANE, 94005, United States |
| Web | http://www.myokardia.com/ |
| Phone | +1 650 7410900 |
| Contact | Michelle Corral (IR Contact Officer) |
| Auditors | PricewaterhouseCoopers LLP |
As of 16/11/20, shares in MyoKardia Inc are trading at $224.91, giving the company a market capitalisation of ÂŁ8.83bn. This share price information is delayed by 15 minutes.
Shares in MyoKardia Inc are currently trading at $224.91 and the price has moved by 0.309k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the MyoKardia Inc price has moved by 0.259k% over the past year.
Of the analysts with advisory recommendations for MyoKardia Inc, there are there are currently 0 "buy" , 9 "hold" and 0 "sell" recommendations. The overall consensus recommendation for MyoKardia Inc is Hold. You can view the full broker recommendation list by unlocking its StockReport.
MyoKardia Inc is scheduled to issue upcoming financial results on the following dates:
MyoKardia Inc does not currently pay a dividend.
MyoKardia Inc does not currently pay a dividend.
MyoKardia Inc does not currently pay a dividend.
To buy shares in MyoKardia Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in MyoKardia Inc are currently trading at $224.91, giving the company a market capitalisation of ÂŁ8.83bn.
Here are the trading details for MyoKardia Inc:
We were not able to load our ranking data for MyoKardia Inc
Shares in MyoKardia Inc are currently priced at $224.91. At that level they are trading at 4.5% premium to the analyst consensus target price of 0.00.
Analysts covering MyoKardia Inc currently have a consensus Earnings Per Share (EPS) forecast of -5.659 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like MyoKardia Inc. Over the past six months, the relative strength of its shares against the market has been 77.81%. At the current price of $224.91, shares in MyoKardia Inc are trading at % against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for MyoKardia Inc.
We were unable to find the directors for MyoKardia Inc.
Here are the top five shareholders of MyoKardia Inc based on the size of their shareholding:
